Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sage Therapeutics Inc.

www.sagerx.com

Latest From Sage Therapeutics Inc.

Sage Plans New Trials And Approval Timeline For Zuranolone

Sage will initiate three new trials to support FDA approval of the drug for post-partum depression and major depressive disorder, with data anticipated in 2021.

Neurology Clinical Trials

VistaGen Hopes To Bounce Back With Spray-Based Depression Drug

NASDAQ-listed company’s shares were reduced to penny stock after trial failures in 2019, but nasal spray PH10 offers glimmer of hope.

Commercial Companies

Sage's Regulatory Strategy For Zuranolone Remains Uncertain

The company said it will update investors on the path forward for zuranolone in major depressive disorder after finalizing discussions with the US FDA. It would not confirm if a meeting had taken place yet.

Neurology Sales & Earnings

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).

Drug Review Drug Approval Standards
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • SAGE Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sage Therapeutics Inc.
  • Senior Management
  • Jeffrey M Jonas, MD, CEO
    Kimi Iguchi, CFO
    Albert J Robichaud, PhD, CSO
    Stephen Kanes, MD, PhD, CMO
    Amy Schacterle, PhD, SVP, Regulatory Affairs & Quality Assurance
    Jim Doherty, PhD, Chief Research Officer
    Mike Cloonan, Chief Bus. Officer
  • Contact Info
  • Sage Therapeutics Inc.
    Phone: (617) 299-8380
    215 First St.
    Cambridge, MA 02142
    USA
UsernamePublicRestriction

Register